Lechner, Katharina
Heel, Sarah
Uhr, Manfred
Dose, Tatjana
Holsboer, Florian
Lucae, Susanne
Schaaf, Ludwig
Fulda, Stephany
Kloiber, Stefan
Hennings, Johannes M.
Funding for this research was provided by:
Max Planck Institute of Psychiatry
Article History
Received: 29 January 2023
Accepted: 23 February 2023
First Online: 9 March 2023
Declarations
:
: The study was approved by the local Ethics Committee of the Medical Faculty at the Ludwig Maximilians University, Munich, Germany and was carried out in accordance with the latest revision of the Declaration of Helsinki.
: KL, SH, MU, TD, SL, LS, SF, SK and JMH have no conflict to declare with respect to this manuscript. FH is cofounder of the biotech company HolsboerMaschmeyerNeuroChemie GmbH (HMNC GmbH) in Germany. FH and MU are co-inventors on the following patent applications: “FKBP5: a novel target for antidepressant therapy” (international application number WO 2005/054500) and “Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments” (international application number PCT/ EP2005/005194).